Legal & General Group Plc Sells 14,991 Shares of TG Therapeutics, Inc. $TGTX

Legal & General Group Plc reduced its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 3.9% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 366,141 shares of the biopharmaceutical company’s stock after selling 14,991 shares during the period. Legal & General Group Plc’s holdings in TG Therapeutics were worth $13,177,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in TGTX. Wellington Management Group LLP boosted its holdings in TG Therapeutics by 1,809.9% in the first quarter. Wellington Management Group LLP now owns 1,213,039 shares of the biopharmaceutical company’s stock valued at $47,830,000 after acquiring an additional 1,149,526 shares during the last quarter. Driehaus Capital Management LLC acquired a new position in TG Therapeutics during the 1st quarter valued at about $30,545,000. Nuveen LLC bought a new position in shares of TG Therapeutics in the 1st quarter valued at about $29,442,000. Woodline Partners LP acquired a new stake in shares of TG Therapeutics during the 1st quarter worth approximately $21,021,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in shares of TG Therapeutics by 1,221.4% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 422,078 shares of the biopharmaceutical company’s stock worth $15,191,000 after buying an additional 390,137 shares during the period. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Stock Down 0.7%

Shares of TGTX stock opened at $33.19 on Friday. TG Therapeutics, Inc. has a 12-month low of $25.28 and a 12-month high of $46.48. The company has a quick ratio of 2.96, a current ratio of 3.86 and a debt-to-equity ratio of 0.89. The firm has a fifty day moving average of $33.87 and a 200-day moving average of $33.91. The company has a market capitalization of $5.27 billion, a price-to-earnings ratio of 89.69 and a beta of 1.95.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $2.43 EPS for the quarter, beating the consensus estimate of $0.24 by $2.19. The business had revenue of $161.71 million for the quarter, compared to analysts’ expectations of $152.12 million. TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The firm’s revenue was up 92.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.02 EPS. TG Therapeutics has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on TGTX. HC Wainwright started coverage on shares of TG Therapeutics in a report on Monday, October 6th. They issued a “buy” rating and a $60.00 price objective on the stock. Weiss Ratings reissued a “hold (c+)” rating on shares of TG Therapeutics in a research note on Tuesday. Wall Street Zen raised TG Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. B. Riley upgraded TG Therapeutics to a “strong-buy” rating in a report on Tuesday, November 4th. Finally, JPMorgan Chase & Co. increased their target price on TG Therapeutics from $46.00 to $49.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $50.25.

Insider Activity

In other TG Therapeutics news, Director Sagar Lonial sold 20,852 shares of the business’s stock in a transaction that occurred on Thursday, September 11th. The stock was sold at an average price of $32.24, for a total value of $672,268.48. Following the sale, the director owned 94,061 shares in the company, valued at approximately $3,032,526.64. The trade was a 18.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Yann Echelard sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $32.57, for a total value of $162,850.00. Following the transaction, the director directly owned 223,816 shares of the company’s stock, valued at approximately $7,289,687.12. This trade represents a 2.19% decrease in their position. The SEC filing for this sale provides additional information. 10.64% of the stock is owned by corporate insiders.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.